Replies to post #125706 on Anavex Life Sciences Corp (AVXL)

[XenaLives]

As another poster pointed out, I was in error. It's going on three years.

Why the hell should they go for something like "hippocampal shrinkage" when quality of life is staring them in the face.

Do you believe the 99.6% failure rate for Alzheimer’s trials doesn’t apply to Anavex because A2-73 is targeting Sigma 1 and not A-beta and Plaques?

Duh yeah, since almost everyone was banging on the same door for 20 years.... and then we have the piano player, the painter, the golfer, etc.

More obfuscation IMO.

[Investor2014]

“Do you believe the 99.6% failure rate for Alzheimer’s trials doesn’t apply to Anavex because A2-73 is targeting Sigma 1 and not A-beta and Plaques?”

In a sense we might need to reset the counter from an ‘A-beta plaque’ one to a new one counting alternative approaches, which includes Donepezil and starts at let’s say 60% failure rate (I don’t know exactly how many non-A-beta drugs have made it into a registration trial).

Dr. Perry reckoned that we are nearer 99.8% failure on the plaque attempts with recent failures by Lundbeck, Biogen mand others.

Perhaps A2-73 has a say 50% chance of reducing the failure rate counter in the non-plaque class.

The other points you raise from the now vTv drug’s past attempts could be valid considerations.

Interesting and exciting what happens over the next 1 to 2 years.